We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals

19 hedge funds and large institutions have $2.99M invested in Tonix Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

0% less ownership

Funds ownership: 0%0% (-0%)

17% less funds holding

Funds holding: 2319 (-4)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

73% less capital invested

Capital invested by funds: $11.1M → $2.99M (-$8.14M)

Holders
19
Holders Change
-4
Holders Change %
-17.39%
% of All Funds
0.33%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
7
Reduced
3
Closed
9
Calls
Puts
Net Calls
Net Calls Change

TNXP Hedge Fund Activity: Q3 2022 in Review

19 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2022, worth a combined $2.99M — down 73% from $11.1M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TNXP and 5 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.52M. The largest seller was Murchinson, exiting entirely with an estimated $5.05M sold.

  • 19 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2022, down from 23 in Q2 2022.
  • Funds reported $2.99M of Tonix Pharmaceuticals stock for Q3 2022, down 73% quarter-over-quarter.
  • 5 funds opened new Tonix Pharmaceuticals positions in Q3 2022 and 9 closed out, a net change of -4 holders.
  • The largest Tonix Pharmaceuticals buyer in Q3 2022 was Renaissance Technologies, an estimated $1.52M added.
  • The largest Tonix Pharmaceuticals seller in Q3 2022 was Murchinson, an estimated $5.05M sold.

Based on aggregated 13F filings for Q3 2022.